 |
 |
|
 |
|
  |
|
|
 |
|
|
Changing Therapy in Relapsing MS
|
|
|
|
|
 |
|
The selection of drug therapy is critical to the management of patients with relapsing multiple sclerosis (MS). In this case-based program, three MS experts will review the available treatment options, and present their views on selecting and switching therapies with the goal of achieving...
|
|
|
|
Steven L. Galetta, MD
(Program Chair)
Robert J. Fox, MD
Clyde E. Markowitz, MD
|
|
|
 |
|
|
 |
|
|
|
 |
I have a patient with left ON 2 days ago with MRI consistent with MS w/o any enhancement on either ON or PVWM. Now she saw an Opthalmologist started her on 80 mg of prednisone. What are
the chances that she may gain her vision back? |
|
|
|
|
 |
Return of visual acuity after about of optic neuritis can, of course, be quite variable, but often can amount to significant return towards her previous acuity over a several weeks to months period of time. Her progress can be monitored by serial visual acuity testing as well as visual field mapping, if an initial scotoma was identified
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
Multiple sclerosis is a chronic disease, having effective treatments but no cure. Understanding of the clinical manifestations and the pathophysiology that leads to them is crucial for all of the professionals who treat, educate and advise patients.
|
|
Robert Fox, MD
Michael Kaufman, MD
Marie Namey, RN, MSN, MSCN |
|
 |
|
 |
|
|
|
|
|
This educational activity presents experts in the field discussing the challenges in the management of patients with multiple sclerosis, including a review of the epidemiology of multiple sclerosis, the costs of care and the role and the cost-effectiveness of disease-modifying therapies.
|
|
Howard S. Rossman, DO
Debra J. Stern, RPh
Sheldon J. Rich, RPh, PhD |
|
|
|
